Market Checkup: Merck
In today's edition of Market Checkup, health-care analysts David Williamson and Max Macaluso take a close look at Merck, a Dow component and one of the biggest players in the pharmaceutical industry. They analyze the highlights from Merck's second-quarter results and examine the company's main vulnerabilities.
One of the best parts of owning big pharma stocks is their attractive dividends, but smart investors know the importance of diversifying -- seeking high-yielding stocks from multiple industries. The Motley Fool's special free report "Secure Your Future With 9 Rock-Solid Dividend Stocks" outlines the Fool's favorite dependable dividend-paying stocks across all sectors. Grab your free copy by clicking here.
The article Market Checkup: Merck originally appeared on Fool.com.David Williamson owns shares of Pfizer. Max Macaluso, Ph.D. owns shares of Gilead Sciences. The Motley Fool recommends Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.